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Introduction
HIV and hepatitis C virus (HCV) are a major cause of morbidity and mortality, and both viruses contain high genomic variation. To date, 
viral gene sequencing has been handled by standard Sanger sequencing (SSS) for the detection of specific drug-resistance determinants 
for HIV and HCV. However, SSS-derived information is limited. By contrast, full-length viral gene sequences when linked to clinical data 
might influence the monitoring of drug resistance to optimally guide treatment, identify sources of viral transmissions within health-care 
settings, and track emerging epidemics. The ICONIC (Infection Response through Virus Genomics) study aims to introduce a novel 
method called next generation sequencing (NGS) within UK health-care settings, testing potential implementation in routine practice. 
With use of samples within established diagnostic laboratory workflows, NGS has the potential to produce higher informational content 
than SSS and report in a timely fashion. However, economic evidence for this emerging method is scarce. 
Aims
To use the examples of HIV and HCV to compare the cost of NGS versus SSS.
Methods 
We performed a bottom-up cost analysis using published, genomic-testing, costing templates to estimate the mean cost per sample for SSS 
and NGS methods over a 1 year period at a major London hospital. Data on resource use associated with genomic testing were based on 
estimates from individual sample data, routinely collected from a UK population.  
Results 
With SSS, mean cost per sample, including operating costs, was £178 for HCV (2080 samples) and £79 for HIV (520). Mean cost per 
sample with NGS was £119 (2207 samples, including operating costs), generating a cost saving of £59 for HCV and a surplus of £40 for 
HIV. 
Conclusions
Although this method is still research based and prices vary widely, our results demonstrated a broad NGS and SSS cost equivalence. 
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HCV cost category HIV cost category
Sample size 2080 520
Equipment Consumables Staff Miscellaneous All categories Equipment Consumables Staff Miscellaneous All categories
Stage 
Clinical sample booking in (plasma, tissue, stool etc)
£4.51 £0.02 £0.04 £5.00 £9.57 £1.13 £0.02 £0.02 £1.25 £2.42
Clinical sample testing (Nucleic acid extraction both 
DNA and RNA) £50.81 £3.08 £2.58 - £56.47 £12.70 £3.08 £0.64 - £16.42
Reverse transcription and genome amplification by 
targeted PCR to generate amplicon 3-6 hours
£4.18 £12.76 £2.58 £0.64 £20.16 £1.05 £16.77 £0.84 - £18.66
Standard Sanger Sequencing run time 5-8 hours
£37.90 £12.16 £1.16 - £51.22 £9.47 £12.83 £0.58 - £22.88
Standard sanger sequencing data analysis 2 hours
£0.64 - £1.55 - £2.19 £0.16 - £1.55 £0.16 £1.87
Total (before overheads)
£98.84 £28.01 £7.91 £5.64 £140.40 £24.51 £32.69 £3.63 £1.41 £62.24
% total cost
70% 20% 6% 4% - 39% £52% 6% 2% -
Total (including overheads at 27.5%)
£125.01 £10.08 £35.72 £7.20 £178.00 £31.25 £41.68 £4.62 £1.80 £79.35
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Table 1: HCV and HIV bottom up cost per sample
Viral infections represent a significant burden to the NHS and a continuing threat to human health with national treatment and
care costs for influenza pandemics for example in excess of £2billion. The effect of virus outbreaks is difficult to calculate
because of the often very constraint time windows in which patients and their linked data need to be processed, interpreted and
actioned upon and the high number of related patient co-morbidities.
Until recently the investigation of viral transmission during an outbreak was challenging as molecular typing models such as
Sanger Sequencing (SSS) had low discriminatory power and their informative value on infection control measures was limited,
resulting in reduced outbreak containment and increasing healthcare costs. This is set to change with Next Generation
Sequencing (NGS) which provides the maximum possible discrimination between closely related viral strains. Here we present
the preliminary results from the Infection Control through Viral Genomics (ICONIC) project, a flagship Health Innovation
Challenge Fund project with the aim or introducing NGS processes into routine NHS operations for the effective detection and
surveillance of viruses and improved stratification of patients.
Figure 1: The ICONIC workflow in relation to the existing virology clinical pathway (shaded box).
